^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SKB315

    i
    Other names: SKB 315, SKB315, MK-1200, SKB-315, MK1200, MK 1200
    Associations

    News

    Trials
    Company:
    Sichuan Kelun Pharma
    Drug class:
    Topoisomerase I inhibitor, CLDN18.2-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    17d
    SKB315-I-01: A Study of SKB315 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=246, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Trial completion date: Feb 2026 --> Jun 2028 | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    CLDN18 (Claudin 18)
    |
    capecitabine • SKB315 • tagitanlimab (HBM9167)
    5ms
    Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002) (clinicaltrials.gov)
    P1/2, N=304, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    SKB315
    7ms
    A Study of SKB315 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=206, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Trial completion date: May 2024 --> Feb 2026 | Trial primary completion date: May 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    CLDN18 (Claudin 18)
    |
    SKB315
    8ms
    Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002) (clinicaltrials.gov)
    P1/2, N=304, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jan 2026 --> Jun 2025 | Trial primary completion date: Jan 2026 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    SKB315
    over1year
    MK-1200-002: Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=304, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    SKB315
    over1year
    Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=304, Recruiting, Merck Sharp & Dohme LLC | Phase classification: P2 --> P1/2 | Trial completion date: Mar 2027 --> Jan 2026 | Trial primary completion date: Jan 2027 --> Jan 2026
    Phase classification • Trial completion date • Trial primary completion date • Metastases
    |
    SKB315
    almost2years
    Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=304, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    SKB315
    almost2years
    Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=304, Not yet recruiting, Merck Sharp & Dohme LLC
    New P2 trial • Metastases
    |
    SKB315
    over3years
    A Study of SKB315 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=206, Recruiting, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
    New P1 trial
    |
    CLDN18 (Claudin 18)
    |
    SKB315